Cargando…
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
BACKGROUND: CUPISCO is an ongoing randomized phase II trial (NCT03498521) comparing molecularly guided therapy versus platinum‐based chemotherapy in patients newly diagnosed with “unfavorable” cancer of unknown primary (CUP). MATERIALS AND METHODS: Patients with an unfavorable CUP diagnosis, as defi...
Autores principales: | Pauli, Chantal, Bochtler, Tilmann, Mileshkin, Linda, Baciarello, Giulia, Losa, Ferran, Ross, Jeffrey S., Pentheroudakis, George, Zarkavelis, George, Yalcin, Suayib, Özgüroğlu, Mustafa, Beringer, Andreas, Scarato, Jeremy, Mueller‐Ohldach, Mathis, Thomas, Marlene, Moch, Holger, Krämer, Alwin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100559/ https://www.ncbi.nlm.nih.gov/pubmed/33687747 http://dx.doi.org/10.1002/onco.13744 |
Ejemplares similares
-
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
por: Ross, Jeffrey S., et al.
Publicado: (2020) -
Cancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice
por: Mileshkin, Linda, et al.
Publicado: (2022) -
Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?
por: Bochtler, Tilmann, et al.
Publicado: (2019) -
ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
por: Catanese, Silvia, et al.
Publicado: (2020) -
Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)